Intellectual Property Filing and Protection Remains a Top Priority OXFORD, Ohio and COCONUT CREEK, Fla., Nov. 19, 2021 /CNW/ – PsyBio Therapeutics Corp. (TSXV: PSYB) (OTCQB: PSYBF) (“PsyBio” or the “Company“), an intellectual property driven biotechnology company developing new, bespoke, psycho-targeted therapeutics to potentially improve mental and neurological health, today announced that it has…


Previous articleTryp Therapeutics Provides Update on Clinical Hold for Phase 2a Study for Eating Disorders
Next articleNuminus to Host Q4 and 2021 Annual Results Conference Call on December 9, 2021